 |
|
|
| |
Efficacy and Safety of Switching to Dolutegravir/Lamivudine by Baseline Regimen
in Virologically Suppressed Adults: 48-Week Pooled Analysis
|
| |
| |
AIDS 2022 July 29-Aug 1 Montreal
Stefan Scholten,1 Pedro Cahn,2 Peter Ruane,3 Richard Kaplan,4 Joaquín Portilla,5 Sally Hodder,6 Fiona Bisshop,7 Brian R. Wynne,8 Richard Grove,9 Gilda Bontempo,8
Riya Moodley,10 Bryn Jones,10 Mounir Ait-Khaled,10 Chinyere Okoli10
1Praxis Hohenstaufenring, Cologne, Germany; 2Fundación Huésped, Buenos Aires, Argentina; 3Ruane Clinical Research, Los Angeles, CA, USA; 4Desmond Tutu Health Foundation, Cape Town, South Africa;
5Hospital General Universitario de Alicante, Alicante, Spain; 6School of Medicine, West Virginia University, Morgantown, WV, USA; 7Holdsworth House Medical Brisbane, Queensland, Australia; 8ViiV Healthcare,
Durham, NC, USA; 9GSK, Brentford, UK; 10ViiV Healthcare, Brentfor, UK
|
| |
|
|
|
|
|
